Twist Bioscience Corporation (NASDAQ: TWST) Stock Competitors & Peer Comparison

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while DHR-PB trades at $1,261.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, TWST's ROE is -0.17%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, TWST is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for TWST.Check DHR-PB's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, TMO has a market cap of 213.4B. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while TMO trades at $574.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas TMO's P/E ratio is 24.79. In terms of profitability, TWST's ROE is -0.17%, compared to TMO's ROE of +0.13%. Regarding short-term risk, TWST is more volatile compared to TMO. This indicates higher risk in terms of short-term price fluctuations for TWST.Check TMO's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, DHR has a market cap of 137.1B. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while DHR trades at $194.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas DHR's P/E ratio is 24.45. In terms of profitability, TWST's ROE is -0.17%, compared to DHR's ROE of +0.08%. Regarding short-term risk, TWST is more volatile compared to DHR. This indicates higher risk in terms of short-term price fluctuations for TWST.Check DHR's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, IDXX has a market cap of 44.1B. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while IDXX trades at $559.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas IDXX's P/E ratio is 41.17. In terms of profitability, TWST's ROE is -0.17%, compared to IDXX's ROE of +0.71%. Regarding short-term risk, TWST is more volatile compared to IDXX. This indicates higher risk in terms of short-term price fluctuations for TWST.Check IDXX's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, A has a market cap of 39.1B. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while A trades at $138.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas A's P/E ratio is 23.82. In terms of profitability, TWST's ROE is -0.17%, compared to A's ROE of +0.21%. Regarding short-term risk, TWST is more volatile compared to A. This indicates higher risk in terms of short-term price fluctuations for TWST.Check A's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, IQV has a market cap of 38.7B. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while IQV trades at $235.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas IQV's P/E ratio is 19.38. In terms of profitability, TWST's ROE is -0.17%, compared to IQV's ROE of +0.22%. Regarding short-term risk, TWST is more volatile compared to IQV. This indicates higher risk in terms of short-term price fluctuations for TWST.Check IQV's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, NTRA has a market cap of 38.3B. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while NTRA trades at $267.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas NTRA's P/E ratio is -168.40. In terms of profitability, TWST's ROE is -0.17%, compared to NTRA's ROE of -0.15%. Regarding short-term risk, TWST is more volatile compared to NTRA. This indicates higher risk in terms of short-term price fluctuations for TWST.Check NTRA's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, ILMN has a market cap of 31B. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while ILMN trades at $205.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas ILMN's P/E ratio is 40.78. In terms of profitability, TWST's ROE is -0.17%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, TWST is less volatile compared to ILMN. This indicates lower risk in terms of short-term price fluctuations for TWST.Check ILMN's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, MTD has a market cap of 28.6B. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while MTD trades at $1,416.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas MTD's P/E ratio is 32.58. In terms of profitability, TWST's ROE is -0.17%, compared to MTD's ROE of -12.00%. Regarding short-term risk, TWST is less volatile compared to MTD. This indicates lower risk in terms of short-term price fluctuations for TWST.Check MTD's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, DGX has a market cap of 25.7B. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while DGX trades at $233.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas DGX's P/E ratio is 22.98. In terms of profitability, TWST's ROE is -0.17%, compared to DGX's ROE of +0.14%. Regarding short-term risk, TWST is more volatile compared to DGX. This indicates higher risk in terms of short-term price fluctuations for TWST.Check DGX's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, LH has a market cap of 25.4B. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while LH trades at $309.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas LH's P/E ratio is 18.36. In terms of profitability, TWST's ROE is -0.17%, compared to LH's ROE of +0.12%. Regarding short-term risk, TWST is more volatile compared to LH. This indicates higher risk in terms of short-term price fluctuations for TWST.Check LH's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, WAT has a market cap of 24.6B. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while WAT trades at $377.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas WAT's P/E ratio is 27.78. In terms of profitability, TWST's ROE is -0.17%, compared to WAT's ROE of +0.08%. Regarding short-term risk, TWST is more volatile compared to WAT. This indicates higher risk in terms of short-term price fluctuations for TWST.Check WAT's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, GH has a market cap of 21.5B. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while GH trades at $161.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas GH's P/E ratio is -62.79. In terms of profitability, TWST's ROE is -0.17%, compared to GH's ROE of +2.11%. Regarding short-term risk, TWST is less volatile compared to GH. This indicates lower risk in terms of short-term price fluctuations for TWST.Check GH's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while EXAS trades at $104.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas EXAS's P/E ratio is -95.37. In terms of profitability, TWST's ROE is -0.17%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, TWST is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for TWST.Check EXAS's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while ILMNV trades at $107.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas ILMNV's P/E ratio is N/A. In terms of profitability, TWST's ROE is -0.17%, compared to ILMNV's ROE of N/A. Regarding short-term risk, TWST is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for TWST.Check ILMNV's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, MEDP has a market cap of 16.1B. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while MEDP trades at $577.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas MEDP's P/E ratio is 36.27. In terms of profitability, TWST's ROE is -0.17%, compared to MEDP's ROE of +1.10%. Regarding short-term risk, TWST is more volatile compared to MEDP. This indicates higher risk in terms of short-term price fluctuations for TWST.Check MEDP's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while PKI trades at $115.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas PKI's P/E ratio is 41.45. In terms of profitability, TWST's ROE is -0.17%, compared to PKI's ROE of +0.03%. Regarding short-term risk, TWST is more volatile compared to PKI. This indicates higher risk in terms of short-term price fluctuations for TWST.Check PKI's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, RVTY has a market cap of 12.6B. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while RVTY trades at $112.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas RVTY's P/E ratio is 21.98. In terms of profitability, TWST's ROE is -0.17%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, TWST is more volatile compared to RVTY. This indicates higher risk in terms of short-term price fluctuations for TWST.Check RVTY's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, ICLR has a market cap of 12.5B. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while ICLR trades at $163.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas ICLR's P/E ratio is 13.34. In terms of profitability, TWST's ROE is -0.17%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, TWST is more volatile compared to ICLR. This indicates higher risk in terms of short-term price fluctuations for TWST.Check ICLR's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, CRL has a market cap of 11.2B. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while CRL trades at $232.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas CRL's P/E ratio is 23.25. In terms of profitability, TWST's ROE is -0.17%, compared to CRL's ROE of -0.06%. Regarding short-term risk, TWST is more volatile compared to CRL. This indicates higher risk in terms of short-term price fluctuations for TWST.Check CRL's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, QGEN has a market cap of 8.5B. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while QGEN trades at $41.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas QGEN's P/E ratio is 17.25. In terms of profitability, TWST's ROE is -0.17%, compared to QGEN's ROE of +0.11%. Regarding short-term risk, TWST is more volatile compared to QGEN. This indicates higher risk in terms of short-term price fluctuations for TWST.Check QGEN's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, BLLN has a market cap of 6.4B. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while BLLN trades at $138.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas BLLN's P/E ratio is 252.00. In terms of profitability, TWST's ROE is -0.17%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, TWST is more volatile compared to BLLN. This indicates higher risk in terms of short-term price fluctuations for TWST.Check BLLN's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, SHC has a market cap of 5.1B. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while SHC trades at $17.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas SHC's P/E ratio is 19.84. In terms of profitability, TWST's ROE is -0.17%, compared to SHC's ROE of +0.21%. Regarding short-term risk, TWST is more volatile compared to SHC. This indicates higher risk in terms of short-term price fluctuations for TWST.Check SHC's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, RDNT has a market cap of 5B. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while RDNT trades at $63.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas RDNT's P/E ratio is 138.65. In terms of profitability, TWST's ROE is -0.17%, compared to RDNT's ROE of -0.01%. Regarding short-term risk, TWST is more volatile compared to RDNT. This indicates higher risk in terms of short-term price fluctuations for TWST.Check RDNT's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while SYNH trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas SYNH's P/E ratio is 61.40. In terms of profitability, TWST's ROE is -0.17%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, TWST is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for TWST.Check SYNH's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, VCYT has a market cap of 3.7B. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while VCYT trades at $46.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas VCYT's P/E ratio is 23.16. In terms of profitability, TWST's ROE is -0.17%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, TWST is less volatile compared to VCYT. This indicates lower risk in terms of short-term price fluctuations for TWST.Check VCYT's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while OLK trades at $26.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas OLK's P/E ratio is -96.59. In terms of profitability, TWST's ROE is -0.17%, compared to OLK's ROE of -0.07%. Regarding short-term risk, TWST is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for TWST.Check OLK's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, NEOG has a market cap of 2.6B. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while NEOG trades at $12.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas NEOG's P/E ratio is 43.00. In terms of profitability, TWST's ROE is -0.17%, compared to NEOG's ROE of -0.00%. Regarding short-term risk, TWST is less volatile compared to NEOG. This indicates lower risk in terms of short-term price fluctuations for TWST.Check NEOG's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, CDNA has a market cap of 2.3B. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while CDNA trades at $43.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas CDNA's P/E ratio is 52.04. In terms of profitability, TWST's ROE is -0.17%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, TWST is less volatile compared to CDNA. This indicates lower risk in terms of short-term price fluctuations for TWST.Check CDNA's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, PSNL has a market cap of 1.4B. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while PSNL trades at $12.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas PSNL's P/E ratio is -12.41. In terms of profitability, TWST's ROE is -0.17%, compared to PSNL's ROE of -0.44%. Regarding short-term risk, TWST is more volatile compared to PSNL. This indicates higher risk in terms of short-term price fluctuations for TWST.Check PSNL's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, CSTL has a market cap of 849.2M. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while CSTL trades at $28.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas CSTL's P/E ratio is -63.64. In terms of profitability, TWST's ROE is -0.17%, compared to CSTL's ROE of -0.04%. Regarding short-term risk, TWST is less volatile compared to CSTL. This indicates lower risk in terms of short-term price fluctuations for TWST.Check CSTL's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while GRALV trades at $18.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas GRALV's P/E ratio is N/A. In terms of profitability, TWST's ROE is -0.17%, compared to GRALV's ROE of N/A. Regarding short-term risk, TWST is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for TWST.Check GRALV's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, FLGT has a market cap of 470M. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while FLGT trades at $16.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas FLGT's P/E ratio is 1655.00. In terms of profitability, TWST's ROE is -0.17%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, TWST is less volatile compared to FLGT. This indicates lower risk in terms of short-term price fluctuations for TWST.Check FLGT's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while CO trades at $2.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas CO's P/E ratio is 5.06. In terms of profitability, TWST's ROE is -0.17%, compared to CO's ROE of +0.11%. Regarding short-term risk, TWST is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for TWST.Check CO's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, NEO has a market cap of 392.9M. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while NEO trades at $15.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas NEO's P/E ratio is 117.62. In terms of profitability, TWST's ROE is -0.17%, compared to NEO's ROE of -0.06%. Regarding short-term risk, TWST is more volatile compared to NEO. This indicates higher risk in terms of short-term price fluctuations for TWST.Check NEO's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, PRENW has a market cap of 360.8M. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while PRENW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas PRENW's P/E ratio is N/A. In terms of profitability, TWST's ROE is -0.17%, compared to PRENW's ROE of -0.47%. Regarding short-term risk, TWST is more volatile compared to PRENW. This indicates higher risk in terms of short-term price fluctuations for TWST.Check PRENW's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, PRE has a market cap of 316.9M. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while PRE trades at $18.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas PRE's P/E ratio is -9.05. In terms of profitability, TWST's ROE is -0.17%, compared to PRE's ROE of -0.47%. Regarding short-term risk, TWST is less volatile compared to PRE. This indicates lower risk in terms of short-term price fluctuations for TWST.Check PRE's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while FLDM trades at $3.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas FLDM's P/E ratio is -4.74. In terms of profitability, TWST's ROE is -0.17%, compared to FLDM's ROE of +0.17%. Regarding short-term risk, TWST is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for TWST.Check FLDM's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, MYGN has a market cap of 270.1M. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while MYGN trades at $2.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas MYGN's P/E ratio is -22.00. In terms of profitability, TWST's ROE is -0.17%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, TWST is less volatile compared to MYGN. This indicates lower risk in terms of short-term price fluctuations for TWST.Check MYGN's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, TRIB has a market cap of 234.9M. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while TRIB trades at $11.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas TRIB's P/E ratio is -3.01. In terms of profitability, TWST's ROE is -0.17%, compared to TRIB's ROE of +0.68%. Regarding short-term risk, TWST is less volatile compared to TRIB. This indicates lower risk in terms of short-term price fluctuations for TWST.Check TRIB's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, BDSX has a market cap of 172.6M. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while BDSX trades at $21.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas BDSX's P/E ratio is -5.22. In terms of profitability, TWST's ROE is -0.17%, compared to BDSX's ROE of -21.01%. Regarding short-term risk, TWST is more volatile compared to BDSX. This indicates higher risk in terms of short-term price fluctuations for TWST.Check BDSX's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, IMDX has a market cap of 150.1M. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while IMDX trades at $4.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas IMDX's P/E ratio is -3.91. In terms of profitability, TWST's ROE is -0.17%, compared to IMDX's ROE of +3.81%. Regarding short-term risk, TWST is more volatile compared to IMDX. This indicates higher risk in terms of short-term price fluctuations for TWST.Check IMDX's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while GTH trades at $4.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas GTH's P/E ratio is -1.11. In terms of profitability, TWST's ROE is -0.17%, compared to GTH's ROE of -1.01%. Regarding short-term risk, TWST is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for TWST.Check GTH's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while GENE trades at $0.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas GENE's P/E ratio is -38.25. In terms of profitability, TWST's ROE is -0.17%, compared to GENE's ROE of -1.85%. Regarding short-term risk, TWST is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for TWST.Check GENE's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, XGN has a market cap of 109.4M. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while XGN trades at $4.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas XGN's P/E ratio is -6.12. In terms of profitability, TWST's ROE is -0.17%, compared to XGN's ROE of -1.14%. Regarding short-term risk, TWST is less volatile compared to XGN. This indicates lower risk in terms of short-term price fluctuations for TWST.Check XGN's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, SERA has a market cap of 79.8M. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while SERA trades at $2.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas SERA's P/E ratio is -3.22. In terms of profitability, TWST's ROE is -0.17%, compared to SERA's ROE of -0.41%. Regarding short-term risk, TWST is similarly volatile compared to SERA. This indicates similar risk in terms of short-term price fluctuations for TWST.Check SERA's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, ATLN has a market cap of 73.2M. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while ATLN trades at $0.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas ATLN's P/E ratio is -0.68. In terms of profitability, TWST's ROE is -0.17%, compared to ATLN's ROE of +14.94%. Regarding short-term risk, TWST is less volatile compared to ATLN. This indicates lower risk in terms of short-term price fluctuations for TWST.Check ATLN's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, DRIO has a market cap of 53.2M. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while DRIO trades at $7.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas DRIO's P/E ratio is -1.24. In terms of profitability, TWST's ROE is -0.17%, compared to DRIO's ROE of +0.93%. Regarding short-term risk, TWST is less volatile compared to DRIO. This indicates lower risk in terms of short-term price fluctuations for TWST.Check DRIO's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, PRPO has a market cap of 38.7M. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while PRPO trades at $21.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas PRPO's P/E ratio is -83.27. In terms of profitability, TWST's ROE is -0.17%, compared to PRPO's ROE of -0.07%. Regarding short-term risk, TWST is less volatile compared to PRPO. This indicates lower risk in terms of short-term price fluctuations for TWST.Check PRPO's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while AKU trades at $0.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas AKU's P/E ratio is -0.13. In terms of profitability, TWST's ROE is -0.17%, compared to AKU's ROE of -5.32%. Regarding short-term risk, TWST is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for TWST.Check AKU's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, MDXH has a market cap of 21.5M. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while MDXH trades at $0.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas MDXH's P/E ratio is -1.10. In terms of profitability, TWST's ROE is -0.17%, compared to MDXH's ROE of +4.03%. Regarding short-term risk, TWST is more volatile compared to MDXH. This indicates higher risk in terms of short-term price fluctuations for TWST.Check MDXH's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while CEMI trades at $0.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas CEMI's P/E ratio is -0.63. In terms of profitability, TWST's ROE is -0.17%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, TWST is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for TWST.Check CEMI's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while ENZ trades at $0.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas ENZ's P/E ratio is -2.24. In terms of profitability, TWST's ROE is -0.17%, compared to ENZ's ROE of -0.10%. Regarding short-term risk, TWST is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for TWST.Check ENZ's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while PMD trades at $2.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas PMD's P/E ratio is -5.24. In terms of profitability, TWST's ROE is -0.17%, compared to PMD's ROE of -0.32%. Regarding short-term risk, TWST is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for TWST.Check PMD's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while ME trades at $0.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas ME's P/E ratio is -0.03. In terms of profitability, TWST's ROE is -0.17%, compared to ME's ROE of -42.03%. Regarding short-term risk, TWST is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for TWST.Check ME's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while MYNZ trades at $3.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas MYNZ's P/E ratio is -0.68. In terms of profitability, TWST's ROE is -0.17%, compared to MYNZ's ROE of -10.25%. Regarding short-term risk, TWST is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for TWST.Check MYNZ's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, QUCY has a market cap of 14.3M. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while QUCY trades at $1.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas QUCY's P/E ratio is -0.05. In terms of profitability, TWST's ROE is -0.17%, compared to QUCY's ROE of -3.26%. Regarding short-term risk, TWST is more volatile compared to QUCY. This indicates higher risk in terms of short-term price fluctuations for TWST.Check QUCY's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, BNGO has a market cap of 12.3M. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while BNGO trades at $1.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas BNGO's P/E ratio is -0.24. In terms of profitability, TWST's ROE is -0.17%, compared to BNGO's ROE of -0.71%. Regarding short-term risk, TWST is less volatile compared to BNGO. This indicates lower risk in terms of short-term price fluctuations for TWST.Check BNGO's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while CHEK trades at $1.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas CHEK's P/E ratio is -0.43. In terms of profitability, TWST's ROE is -0.17%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, TWST is more volatile compared to CHEK. This indicates higher risk in terms of short-term price fluctuations for TWST.Check CHEK's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while CNTG trades at $0.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas CNTG's P/E ratio is -0.23. In terms of profitability, TWST's ROE is -0.17%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, TWST is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for TWST.Check CNTG's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, BNR has a market cap of 9.3M. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while BNR trades at $8.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas BNR's P/E ratio is -10.73. In terms of profitability, TWST's ROE is -0.17%, compared to BNR's ROE of -0.11%. Regarding short-term risk, TWST is more volatile compared to BNR. This indicates higher risk in terms of short-term price fluctuations for TWST.Check BNR's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, ADVB has a market cap of 8.7M. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while ADVB trades at $8.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas ADVB's P/E ratio is -72.73. In terms of profitability, TWST's ROE is -0.17%, compared to ADVB's ROE of -0.21%. Regarding short-term risk, TWST is less volatile compared to ADVB. This indicates lower risk in terms of short-term price fluctuations for TWST.Check ADVB's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, MBAI has a market cap of 7.4M. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while MBAI trades at $1.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas MBAI's P/E ratio is 1.58. In terms of profitability, TWST's ROE is -0.17%, compared to MBAI's ROE of +4.17%. Regarding short-term risk, TWST is less volatile compared to MBAI. This indicates lower risk in terms of short-term price fluctuations for TWST.Check MBAI's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while APDN trades at $5.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas APDN's P/E ratio is -0.10. In terms of profitability, TWST's ROE is -0.17%, compared to APDN's ROE of -6.53%. Regarding short-term risk, TWST is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for TWST.Check APDN's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while NVTA trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas NVTA's P/E ratio is -0.00. In terms of profitability, TWST's ROE is -0.17%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, TWST is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for TWST.Check NVTA's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while LMDXW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, TWST's ROE is -0.17%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, TWST is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for TWST.Check LMDXW's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while LMDX trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas LMDX's P/E ratio is -0.01. In terms of profitability, TWST's ROE is -0.17%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, TWST is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for TWST.Check LMDX's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, NDRA has a market cap of 3.6M. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while NDRA trades at $4.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas NDRA's P/E ratio is -0.61. In terms of profitability, TWST's ROE is -0.17%, compared to NDRA's ROE of -5.13%. Regarding short-term risk, TWST is less volatile compared to NDRA. This indicates lower risk in terms of short-term price fluctuations for TWST.Check NDRA's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while DMTK trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas DMTK's P/E ratio is -0.04. In terms of profitability, TWST's ROE is -0.17%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, TWST is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for TWST.Check DMTK's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, BIAF has a market cap of 2.8M. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while BIAF trades at $0.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas BIAF's P/E ratio is -0.07. In terms of profitability, TWST's ROE is -0.17%, compared to BIAF's ROE of -3.59%. Regarding short-term risk, TWST is less volatile compared to BIAF. This indicates lower risk in terms of short-term price fluctuations for TWST.Check BIAF's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while NOTV trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas NOTV's P/E ratio is -0.03. In terms of profitability, TWST's ROE is -0.17%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, TWST is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for TWST.Check NOTV's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while SQL trades at $6.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas SQL's P/E ratio is -0.40. In terms of profitability, TWST's ROE is -0.17%, compared to SQL's ROE of +38.02%. Regarding short-term risk, TWST is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for TWST.Check SQL's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while AWH trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas AWH's P/E ratio is -0.09. In terms of profitability, TWST's ROE is -0.17%, compared to AWH's ROE of +2.03%. Regarding short-term risk, TWST is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for TWST.Check AWH's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, INBS has a market cap of 1.2M. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while INBS trades at $1.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas INBS's P/E ratio is -0.21. In terms of profitability, TWST's ROE is -0.17%, compared to INBS's ROE of -1.74%. Regarding short-term risk, TWST is less volatile compared to INBS. This indicates lower risk in terms of short-term price fluctuations for TWST.Check INBS's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while HTGM trades at $0.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas HTGM's P/E ratio is -0.03. In terms of profitability, TWST's ROE is -0.17%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, TWST is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for TWST.Check HTGM's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while BIOC trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas BIOC's P/E ratio is -0.01. In terms of profitability, TWST's ROE is -0.17%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, TWST is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for TWST.Check BIOC's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, ISPC has a market cap of 262.4K. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while ISPC trades at $1.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas ISPC's P/E ratio is -0.06. In terms of profitability, TWST's ROE is -0.17%, compared to ISPC's ROE of -5.85%. Regarding short-term risk, TWST is less volatile compared to ISPC. This indicates lower risk in terms of short-term price fluctuations for TWST.Check ISPC's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while SQLLW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, TWST's ROE is -0.17%, compared to SQLLW's ROE of +38.02%. Regarding short-term risk, TWST is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for TWST.Check SQLLW's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while CHEKZ trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, TWST's ROE is -0.17%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, TWST is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for TWST.Check CHEKZ's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while MEUSW trades at $1.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas MEUSW's P/E ratio is N/A. In terms of profitability, TWST's ROE is -0.17%, compared to MEUSW's ROE of -42.03%. Regarding short-term risk, TWST is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for TWST.Check MEUSW's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, OCDX has a market cap of 0. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while OCDX trades at $17.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas OCDX's P/E ratio is -42.28. In terms of profitability, TWST's ROE is -0.17%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, TWST is more volatile compared to OCDX. This indicates higher risk in terms of short-term price fluctuations for TWST.Check OCDX's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while DHR-PA trades at $1,841.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, TWST's ROE is -0.17%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, TWST is more volatile compared to DHR-PA. This indicates higher risk in terms of short-term price fluctuations for TWST.Check DHR-PA's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while BNGOW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas BNGOW's P/E ratio is N/A. In terms of profitability, TWST's ROE is -0.17%, compared to BNGOW's ROE of -0.71%. Regarding short-term risk, TWST is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for TWST.Check BNGOW's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, PRXL has a market cap of 0. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while PRXL trades at $88.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas PRXL's P/E ratio is 42.97. In terms of profitability, TWST's ROE is -0.17%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, TWST is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for TWST.Check PRXL's competition here

Twist Bioscience Corporation (NASDAQ: TWST) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TWST stands at 5.7B. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, TWST is priced at $91.55 on the NASDAQ, while NDRAW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TWST currently has a P/E ratio of -42.98, whereas NDRAW's P/E ratio is N/A. In terms of profitability, TWST's ROE is -0.17%, compared to NDRAW's ROE of -5.13%. Regarding short-term risk, TWST is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for TWST.Check NDRAW's competition here